Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine
TRUDHESA Is the First and Only Therapeutic to Use POD technology to Deliver Dihydroergotamine Mesylate (DHE) to the Vascular-Rich…
Study Compares Nerivio to Standard Care Medications for Acute Treatment of Migraine in Adolescents
Peer-Reviewed Study Compares Treatment Results from Migraine Medications to Using Nerivio’s Remote Electrical Neuromodulation Theranica, a prescribed digital therapeutics…
Nerivio Wearable Migraine Therapeutic Now Eligible for Coverage through UpScript’s Telemedicine Platform
Nerivio Patient Savings Program Allows Eligible Patients to Receive the Prescribed Wearable for Acute Treatment of Migraine for…
FDA Approves Theranica’s Nerivio® for Acute Treatment of Migraine in Adolescents
The Prescribed Wearable Device is Now indicated for Patients 12 Years Old and Above Theranica, a prescribed digital therapeutics (PDT)…
